Loading clinical trials...
Loading clinical trials...
The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UCB Pharma
NCT07184931 · Crohn's Disease
NCT06100289 · Ulcerative Colitis, Crohn's Disease
NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more
NCT06180382 · Crohn's Disease
NCT07545317 · Crohn's Disease
Bonheiden
Brussels
Edegem
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions